TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
By Daniele V. F. Tauriello, Sergio Palomo-Ponce, Diana Stork, A. Berenguer-Llergo, Jordi Badia-Ramentol, M. Iglesias, Marta Sevillano, S. Ibiza, Adrià Cañellas, Xavier Hernando-Momblona and 8 more. Nature, 2018
1,524 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/28d0ccf27439f47f76c4d8227e233af821f0909a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
- Zena Werb
- J. Massagué
- E. Batlle
- Simone Brabletz
- Thomas Brabletz
- P. ten Dijke
- Hugo Gonzalez
- Harald Schuhwerk
In Pathology and Forensic Medicine
Citations in the corpus
- TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis (2019, positive): “For example, regulation of tumor metastasis by TGF-β/SMAD signaling was found to be achieved by impairing the activity of tumor-infiltrating T cells [237,238], i.”
- Targeting TGF-β signal transduction for fibrosis and cancer therapy (2022, background): “An increased KRAS mutation and SMAD mutation in PDAC patients drive early tumorigenesis and metastasis.”
- Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “For example, TAMs and Tregs boost an immune-tolerant TME by secretion of immune-suppressive molecules such as IL-10, TGF-β, and prostaglandins; they also inhibit the secretion of IL-12 by DCs, avoiding themounting of a Th-1 response and excludingNK and effector T cells (Ruffell et al. 2014; Speiser ”
- Transforming Grown Factor-β Signaling in Immunity and Cancer (2019, positive): “Elevated TGF-β levels produced by CAFs and other TME cell types exclude CD4+ and CD8+ T cells from the tumor center (Tauriello et al., 2018).”